Immortalized Placental Stem Cells Enable Scalable, Consistent Extracellular Vesicle Production
hTERT-immortalized placental MSCs produce EVs with stable cargo and validated anti-fibrotic efficacy, solving a key scalability bottleneck.
Summary
Researchers immortalized human placental chorionic mesenchymal stromal cells (hPC-MSCs) using hTERT gene insertion via lentiviral vector, enabling stable proliferation beyond 60 passages without senescence. The resulting immortalized cells (iPC-MSCs) retained normal surface markers, multipotent differentiation capacity, and a normal diploid karyotype. Extracellular vesicles (EVs) harvested from iPC-MSCs closely matched those from primary cells in particle size, protein markers, and overall cargo composition across three independent production batches. In a bleomycin-induced rat pulmonary fibrosis model, iPC-MSC-derived EVs significantly reduced fibrotic damage, outperforming or matching standard drugs dexamethasone and pirfenidone. This platform addresses critical challenges in EV manufacturing including donor variability, limited cell lifespan, and batch inconsistency.
Detailed Summary
Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) have emerged as promising cell-free therapeutic agents due to their immunomodulatory, anti-inflammatory, and tissue-repair properties. However, clinical translation has been hampered by donor heterogeneity, the finite lifespan of primary MSCs, and resulting batch-to-batch variability in EV cargo. This study directly addresses those manufacturing challenges by creating a stable, immortalized MSC line as a renewable EV source.
The team used a second-generation lentiviral system to stably integrate the human telomerase reverse transcriptase (hTERT) gene into primary placental chorionic MSCs (hPC-MSCs), chosen for their fast proliferation, high differentiation potential, and the immune-privileged nature of the placenta. The resulting immortalized iPC-MSCs proliferated continuously for at least 60 passages with no signs of senescence, maintaining fibroblast-like morphology comparable to early-passage primary cells. Critically, surface marker expression (CD73, CD105, CD29, CD90 positive; CD34, CD45 negative), trilineage differentiation potential (osteogenic, adipogenic, chondrogenic), and normal diploid karyotype (46, XY) were all preserved at passage 60, satisfying ISCT minimal criteria for MSC identity.
RNA sequencing comparing passage-3 primary PC-MSCs with passage-60 iPC-MSCs identified 5,165 differentially expressed genes. GO and KEGG analyses linked these differences to immune regulation, ECM organization, and fibrosis-relevant pathways (TGF-β, p53, PI3K-AKT, NF-κB, MAPK), suggesting hTERT overexpression may itself tune the cellular secretome toward an anti-fibrotic phenotype. Despite these transcriptional shifts, EVs isolated from iPC-MSCs closely replicated those of parental cells in particle size distribution, canonical EV protein markers (CD9, CD63, CD81, TSG101, HSP70), and broader proteomic profiles. Proteomic analysis across three independent EV batches confirmed high inter-batch reproducibility—a direct answer to the consistency problem plaguing primary-cell-derived EV manufacturing.
Therapeutic efficacy was validated in a bleomycin-induced rat pulmonary fibrosis model, a well-established preclinical system. iPC-MSC-derived EVs reduced histological fibrosis scores, collagen deposition, and inflammatory markers in a dose-dependent manner, performing comparably to or better than the clinical antifibrotics dexamethasone and pirfenidone. These results confirm that immortalization does not compromise—and may even enhance—the therapeutic potency of the derived EVs.
Overall, this study establishes hTERT-immortalized hPC-MSCs as a validated, scalable platform for consistent EV production, offering a practical solution to major bottlenecks in the field. Caveats include the preclinical nature of the fibrosis model, limited mechanistic dissection of which specific EV cargo components drive efficacy, and the need for longer-term safety and tumorigenicity assessments before clinical translation.
Key Findings
- iPC-MSCs proliferate stably for 60+ passages with preserved MSC surface markers, differentiation potential, and normal karyotype.
- hTERT insertion does not alter EV size distribution, canonical protein markers, or overall proteomic cargo versus primary MSCs.
- Three independent EV batches showed high inter-batch reproducibility in cargo composition, addressing a core manufacturing challenge.
- iPC-MSC EVs significantly reduced bleomycin-induced pulmonary fibrosis in rats, matching or exceeding dexamethasone and pirfenidone.
- RNA-seq identified 5,165 DEGs enriched in TGF-β, NF-κB, and PI3K-AKT pathways, suggesting hTERT may tune an anti-fibrotic secretome.
Methodology
Primary hPC-MSCs were immortalized via lentiviral hTERT overexpression and characterized through flow cytometry, RT-PCR, karyotyping, RNA-seq, and trilineage differentiation assays up to passage 60. EVs were isolated from conditioned media across three independent batches and characterized by NTA, western blotting, and proteomics. Therapeutic efficacy was tested in a bleomycin-induced rat pulmonary fibrosis model with dose-response evaluation and comparison against dexamethasone and pirfenidone.
Study Limitations
All efficacy data are from a rat bleomycin model, which imperfectly recapitulates human idiopathic pulmonary fibrosis; primate or clinical studies are needed. Long-term tumorigenicity and safety of hTERT-immortalized cell-derived products were not fully addressed. The specific EV cargo components responsible for anti-fibrotic activity were not mechanistically isolated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: